PortalPublikationenImatinib after induction for treatment of children and adole...

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.

Standard

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. / Biondi, Andrea; Schrappe, Martin; Paola, De Lorenzo; Castor, Anders; Lucchini, Giovanna; Gandemer, Virginie; Pieters, Rob; Stary, Jan; Escherich, Gabriele; Campbell, Myriam; Li, Chi-Kong; Vora, Ajay; Aricò, Maurizio; Röttgers, Silja; Saha, Vaskar; Valsecchi, Maria Grazia.

in: LANCET ONCOL, Jahrgang 13, Nr. 9, 9, 2012, S. 936-945.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Biondi, A, Schrappe, M, Paola, DL, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Campbell, M, Li, C-K, Vora, A, Aricò, M, Röttgers, S, Saha, V & Valsecchi, MG 2012, 'Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.', LANCET ONCOL, Jg. 13, Nr. 9, 9, S. 936-945. <http://www.ncbi.nlm.nih.gov/pubmed/22898679?dopt=Citation>

APA

Biondi, A., Schrappe, M., Paola, D. L., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., Li, C-K., Vora, A., Aricò, M., Röttgers, S., Saha, V., & Valsecchi, M. G. (2012). Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. LANCET ONCOL, 13(9), 936-945. [9]. http://www.ncbi.nlm.nih.gov/pubmed/22898679?dopt=Citation

Vancouver

Biondi A, Schrappe M, Paola DL, Castor A, Lucchini G, Gandemer V et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. LANCET ONCOL. 2012;13(9):936-945. 9.

Bibtex

@article{691835cc8b2d4c06ac22a9f011ff402c,
title = "Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.",
abstract = "Trials of imatinib have provided evidence of activity in adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given with multidrug chemotherapy to children is unknown. This study assesses the safety and efficacy of oral imatinib in association with a Berlin-Frankfurt-Munster intensive chemotherapy regimen and allogeneic stem-cell transplantation for paediatric patients with Philadelphia-chromosome-positive ALL.",
keywords = "Humans, Male, Female, Adolescent, Child, Risk Assessment, Survival Rate, Disease-Free Survival, Child, Preschool, Incidence, Infant, Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Neoplasm, Residual, Neoplasm Recurrence, Local/epidemiology, *Philadelphia Chromosome, Piperazines/*administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/*genetics/mortality/surgery, Pyrimidines/*administration & dosage, Humans, Male, Female, Adolescent, Child, Risk Assessment, Survival Rate, Disease-Free Survival, Child, Preschool, Incidence, Infant, Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Neoplasm, Residual, Neoplasm Recurrence, Local/epidemiology, *Philadelphia Chromosome, Piperazines/*administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/*genetics/mortality/surgery, Pyrimidines/*administration & dosage",
author = "Andrea Biondi and Martin Schrappe and Paola, {De Lorenzo} and Anders Castor and Giovanna Lucchini and Virginie Gandemer and Rob Pieters and Jan Stary and Gabriele Escherich and Myriam Campbell and Chi-Kong Li and Ajay Vora and Maurizio Aric{\`o} and Silja R{\"o}ttgers and Vaskar Saha and Valsecchi, {Maria Grazia}",
year = "2012",
language = "English",
volume = "13",
pages = "936--945",
journal = "LANCET ONCOL",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

RIS

TY - JOUR

T1 - Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.

AU - Biondi, Andrea

AU - Schrappe, Martin

AU - Paola, De Lorenzo

AU - Castor, Anders

AU - Lucchini, Giovanna

AU - Gandemer, Virginie

AU - Pieters, Rob

AU - Stary, Jan

AU - Escherich, Gabriele

AU - Campbell, Myriam

AU - Li, Chi-Kong

AU - Vora, Ajay

AU - Aricò, Maurizio

AU - Röttgers, Silja

AU - Saha, Vaskar

AU - Valsecchi, Maria Grazia

PY - 2012

Y1 - 2012

N2 - Trials of imatinib have provided evidence of activity in adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given with multidrug chemotherapy to children is unknown. This study assesses the safety and efficacy of oral imatinib in association with a Berlin-Frankfurt-Munster intensive chemotherapy regimen and allogeneic stem-cell transplantation for paediatric patients with Philadelphia-chromosome-positive ALL.

AB - Trials of imatinib have provided evidence of activity in adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given with multidrug chemotherapy to children is unknown. This study assesses the safety and efficacy of oral imatinib in association with a Berlin-Frankfurt-Munster intensive chemotherapy regimen and allogeneic stem-cell transplantation for paediatric patients with Philadelphia-chromosome-positive ALL.

KW - Humans

KW - Male

KW - Female

KW - Adolescent

KW - Child

KW - Risk Assessment

KW - Survival Rate

KW - Disease-Free Survival

KW - Child, Preschool

KW - Incidence

KW - Infant

KW - Stem Cell Transplantation

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Neoplasm, Residual

KW - Neoplasm Recurrence, Local/epidemiology

KW - Philadelphia Chromosome

KW - Piperazines/administration & dosage

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/mortality/surgery

KW - Pyrimidines/administration & dosage

KW - Humans

KW - Male

KW - Female

KW - Adolescent

KW - Child

KW - Risk Assessment

KW - Survival Rate

KW - Disease-Free Survival

KW - Child, Preschool

KW - Incidence

KW - Infant

KW - Stem Cell Transplantation

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Neoplasm, Residual

KW - Neoplasm Recurrence, Local/epidemiology

KW - Philadelphia Chromosome

KW - Piperazines/administration & dosage

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics/mortality/surgery

KW - Pyrimidines/administration & dosage

M3 - SCORING: Journal article

VL - 13

SP - 936

EP - 945

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 9

M1 - 9

ER -